不同剂量布地奈德对变异性哮喘合并嗜酸细胞性支气管炎患者临床症状及痰嗜酸粒细胞计数的影响  

Effect of Different Doses of Budesonide on Symptoms and Sputum Eosinophil Count of CVA Patients with Eosinophilic Bronchitis

作　　者：谭艳[1] 钟薇[1] 

机构地区：[1]成都市新都区人民医院呼吸内科,成都610500

出　　处：《医学综述》2016年第9期1765-1767,1770,共4页Medical Recapitulate

摘　　要：目的探讨不同剂量布地奈德对变异性哮喘(CVA)合并嗜酸细胞性支气管炎(EB)患者临床症状及痰嗜酸粒细胞计数的影响。方法选取自2013年1月至2014年1月在成都市新都区人民医院接受治疗的经确诊为CVA合并EB患者120例,按照随机数字表法分为3组,各40例。3组患者在常规治疗的基础上分别给予不同剂量布地奈德雾化吸入治疗,即为小剂量组(400μg/d)、中剂量组(800μg/d)、大剂量组(1600μg/d),对3组患者治疗后的临床症状进行评分,检测并比较治疗前后的痰嗜酸粒细胞计数情况。结果小剂量组、中剂量组、大剂量组的总有效率分别为67.5%(27/40)、97.5%(39/40)、95.0%(38/40),中剂量组、大剂量组患者的总有效率显著高于小剂量组(P<0.05);但中剂量组与大剂量组总有效率比较差异无统计学意义(P>0.05);治疗后,中剂量组患者的咳嗽症状评分及痰嗜酸粒细胞计数分别为(1.42±0.57)分、(0.72±0.24)%,大剂量组分别为(1.48±0.56)分、(0.69±0.21)%,均显著低于小剂量组(1.84±0.62)分和(1.81±0.76)%,中剂量组、大剂量组患者的咳嗽症状评分及痰嗜酸粒细胞计数显著低于小剂量组(P<0.05);但中剂量组、大剂量组患者症状评分差异无统计学意义(P>0.05)。3组患者治疗后的咳嗽症状评分及痰嗜酸粒细胞计数均较治疗前显著降低,差异有统计学意义(P<0.05)。小剂量组、中剂量组、大剂量组患者的不良反应发生率分别为2.5%(1/40)、2.5%(1/40)、20.0%(8/40),小剂量组、中剂量组显著低于大剂量组(P<0.05);小剂量组、中剂量组比较差异无统计学意义(P>0.05)。结论不同剂量布地奈德雾化吸入治疗对CVA合并EB患者咳嗽症状及痰嗜酸粒细胞计数的改善效果不同,CVA合并EB患者雾化吸入布地奈德的最佳剂量为800μg/d。Objective To investigate the effects of different doses of budesonide on clinical symptoms and sputum eosinophil count of cough variant asthma（CVA） patients with eosinophilic bronchitis（EB）. Methods During Jan. 2013 and Jan. 2014 in Chengdu Xindu District People＇s Hospital 120 CVA patients with EB were included in the study. According to random number table method the patients were divided into three greups,40 cases each,and the three groups,on the basis of conventional therapy,were given different doses of budesonide inhalation therapy, namely low-dose group （400 μg/d）, medium-dose group （800 μg/ d） ,high-dose group （ 1600 μg/d）, and the clinical symptoms of the three groups after treatment were scored,sputum eosinophil count were compared before and after treatment. Results The total effective rate of low-dose group, medium-dose group, the high-dose group were 67.5 % （27/40） ,97.5 % （39/40）, 95.0 % （38/40）, the medium-dose group, high-dose group were significantly higher than the low-dose group （P 〈 0. 05 ） ; but the difference between the medium-dose group and high-dose group was not statistically signifi- cant （ P 〉 0.05 ）. After treatment, the cough score and sputum eosiuophil count of the medium-dose group were （ 1.42 ±0. 57 ）, （0. 72 ± 0. 24 ） %, of the high-dose group were （ 1.48 ± 0. 56 ）, （ 0. 69 ± 0. 21 ） %, all significantly lower than the low-dose group＇ s （ 1.84 ± 0. 62 ） and （ 1.81 ±0.76 ） % （ P 〈 0. 05 ） ; but the difference between the medium-dose group and high-dose group was not statistically significant（ P 〉 0. 05 ）. The cough scores and sputum eosinophil count of all of the three groups after treatment were statistically sig- nificantly lower than before treatment（ P 〈 0. 05 ）. The adverse events rates of the low-dose group, medium- dose group,high dose group were 2.5% （1/40） ,2.5% （1/40） ,20. 0% （8/40） ,low-dose group,medium- dose group significantly lower than the high-dase group �

关 键 词：咳嗽变异性哮喘 嗜酸细胞性支气管炎 布地奈德 嗜酸细胞计数 

分 类 号：R562[医药卫生—呼吸系统]